Moderna Merck Vaccine Cuts Melanoma Recurrence
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna and Merck& Co developed a personalized mRNA vaccine called Intismeran that targets individual tumor mutations after surgical removal and DNA sequencing of the tumor
- Intismeran was administered alongside Keytruda in a trial involving over 1,000 high-risk melanoma patients, leading to a significant increase in time without cancer recurrence compared to Keytruda alone
- Merck and Moderna reported interim results showing the combination therapy reduced the risk of cancer spreading to other organs, though full data has not yet been peer-reviewed or released
- Prof Peter Johnson described the treatment as a major advance because it directs the immune system specifically to cancer cells, unlike previous immunotherapies that broadly activate immunity
- Dr Lennard Lee stated the study provides proof of principle that personalized cancer vaccines work, with implications beyond melanoma for future use in lung, bladder, and kidney cancers
- Stephane Bancel called the findings a 'pivotal moment' in cancer research, while Cancer Research UK's Dr Talisia Quallo emphasized the need for continued funding despite promising early results
Why it matters: Over 1,000 high-risk melanoma patients saw delayed recurrence when using the personalized vaccine with Keytruda, proving targeted mRNA vaccines can work—this shifts cancer treatment from broad immune activation to precision targeting, opening pathways for similar therapies across multiple cancers pending regulatory approval.
Ask SkimNews
